Target type: cellularcomponent
A SWI/SNF-type complex that contains 8 to 14 proteins, including both conserved (core) and nonconserved components; contains the ATPase product of the yeast SNF2 or mammalian SMARCA4/BAF190A/BRG1 gene, or an ortholog thereof. [GOC:bhm, PMID:12672490]
The SWI/SNF complex is a large multi-protein complex that acts as a chromatin remodeler, playing a crucial role in gene regulation. It consists of multiple subunits with distinct functions, each contributing to its overall activity. The core subunits, including the ATPase subunit, are responsible for the complex's ability to alter chromatin structure, while other subunits act as DNA binding or regulatory elements.
The cellular component of the SWI/SNF complex is primarily localized to the nucleus, where it interacts directly with chromatin. It associates with nucleosomes, the basic unit of chromatin, and utilizes the energy derived from ATP hydrolysis to alter their structure. This remodeling activity can involve repositioning nucleosomes, removing or exchanging histones, or unwinding DNA from nucleosomes, ultimately influencing the accessibility of DNA to transcription factors and other regulatory proteins.
The SWI/SNF complex is a dynamic entity, with its composition and activity varying depending on the cell type and its developmental stage. Different subunits can associate with the complex, influencing its targeting and function. The complex's association with specific regions of DNA is often regulated by protein-protein interactions, such as those with transcription factors or other regulatory proteins. This allows for precise control over gene expression in response to various cellular cues.
The SWI/SNF complex plays a critical role in various cellular processes, including cell growth, differentiation, and development. Its dysregulation is implicated in a range of human diseases, including cancer. Mutations or alterations in the expression of SWI/SNF subunits can disrupt its function, leading to uncontrolled cell proliferation or other pathological outcomes.
In summary, the SWI/SNF complex is a multifaceted chromatin remodeler with a complex cellular component. Its activity is tightly regulated and plays a crucial role in regulating gene expression and cellular function. Understanding the composition, activity, and regulation of this complex is essential for understanding its role in normal development and disease.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Bromodomain-containing protein 9 | A bromodomain-containing protein 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9H8M2] | Homo sapiens (human) |
| Protein polybromo-1 | A protein polybromo-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q86U86] | Homo sapiens (human) |
| Transcription activator BRG1 | A transcription activator BRG1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P51532] | Homo sapiens (human) |
| Probable global transcription activator SNF2L2 | A probable global transcription activator SNF2L2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P51531] | Homo sapiens (human) |
| Retinoblastoma-associated protein | A retinoblastoma-associated protein that is encoded in the genome of human. [PRO:DNx, UniProtKB:P06400] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| lobenzarit | lobenzarit: prevents autoimmune kidney disease in hybrid mice; RN given refers to parent cpd | aminobenzoic acid | |
| ferrocin c | N-methyl-2-quinolone: structure in first source | ||
| 3-acetylindole | 3-acetylindole: structure in first source | ||
| staurosporine | indolocarbazole alkaloid; organic heterooctacyclic compound | apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector | |
| tg 003 | TG 003: a Clk inhibitor; structure in first source | ||
| 2,4-Di(3-pyridyl)-1,3-thiazole | thiazoles | ||
| 5-Methyl-6-(2-thienyl)-2,3,4,5-tetrahydropyridazin-3-one | pyridazines | ||
| luteolin | 3'-hydroxyflavonoid; tetrahydroxyflavone | angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist | |
| su 11248 | monocarboxylic acid amide; pyrroles | angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist | |
| i-bet726 | |||
| pf-06687252 | PF-06687252: a SMARCA2/4 bromodomain inhibitor; structure in first source PFI-3 : An azabicycloalkane that is (1R,4R)-2,5-diazabicyclo[2.2.1]heptane which is substituted at position 2 by a 3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl group and at position 5 by a pyridin-2-yl group. It is a potent and selective inhibitor of polybromo 1 (Kd = 48 nM), SMARCA2 and SMARCA4 (Kd = 89 nM) bromodomains. | azabicycloalkane; enone; phenols; pyridines | |
| pf-477736 | PF 00477736: a Chk1 inhibitor; structure in first source PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1). |